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ABSTRACT: The crystalline nutritional supplement Į-lipoic acid degrades rapidly on exposure to 
temperatures above its melting point 65 °C and to light. A small-scale experimental co-crystal screen 
has produced three novel co-crystals of Į-lipoic acid that each display enhanced thermal stability and 
differences in aqueous solubilities compared to Į-lipoic acid. In each case, the initial screening 
procedure produced tens of milligrams of material enabling initial identification, characterisation and 
crystal structure determination. The structure of the Į-lipoic acid:nicotinamide co-crystal was 
determined by single crystal X-ray diffraction and used for subsequent phase identification. Scale-up of 
the co-crystallisation process of Į-lipoic acid with nicotinamide was then investigated in a continuous 
oscillatory baffled crystalliser. Over 1 kg of solid co-crystals was produced using a continuous 
crystallisation process in a continuous oscillatory baffled crystalliser at a throughput of 350 g/hr 
yielding a purity of 99 % demonstrating this as an effective route to rapid scale-up of a novel co-crystal 
system.  
 
*To whom correspondence should be addressed. E-mail: alastair.florence@strath.ac.uk. Telephone:+44-
141-548-4877. Fax: +44-141- 552-2562. 
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INTRODUCTION 
Į-Lipoic acid (ALA; 1,2-dithiolane-3-pentanoic acid, Fig. 1) is an anti-oxidant and essential co-
enzyme1 used as a nutritional supplement with applications in the treatment of diabetic neuropathy2, 3, 
$O]KHLPHU¶V GLVHDVH4, metal poisoning5, 6 and liver disease.7 The molecule is prone to polymerisation 
and photo-decomposition associated with cleavage of the disulfide bond in the 1,2-dithiolane ring8, 9 
(Fig. 1). The crystal structure of ALA is known10 (CSD11: THOCAR01) and various alternative 
crystalline forms with improved chemical stability have been reported including trometamol12, 
carnitine13, sodium and potassium salts.14, 15 Improved stability of ALA has also been achieved by 
formulation of ALA with different components including polymers16 and ȕ-cyclodextrin.17  
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Fig. 1 Chemical structure of D-Lipoic acid (ALA) 
 
Co-crystals18-21 offer a route to engineer critical physico-chemical properties of specialty chemicals 
including pharmaceuticals19, 22, 23 neutraceuticals24, 25, energetic materials26, 27 and agrochemicals.28 
Novel co-crystal forms also offer an opportunity to secure new intellectual property as part of the 
lifecycle management of chemical entities.29 There are a number of examples of systems where co-
crystals have been shown to improve the chemical stability of otherwise labile compounds.30, 31 Co-
crystallisation has also been used as an effective method to purify compounds during their industrial 
scale production.32-34 Approaches to the effective selection of co-crystal formers for specific molecules 
have been widely reported.21, 22, 35-38 Methods include identifying complementary hydrogen bonding 
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motifs21, 37-39 and comparing the relative thermodynamic stabilities of the co-crystal and the component 
solid forms.40 
Many different techniques have been described in the literature for obtaining co-crystal forms including 
solution crystallisation41, 42, slow solvent evaporation43, 44, slurry conversion45, neat46, 47 and liquid 
assisted grinding48 as well as growth from melts.49 Recently, the use of twin-screw extrusion for the 
preparation of pharmaceutical co-crystals has also been reported.50-52 Among these methods, slow 
evaporation and grinding are convenient and efficient ways to produce milligram or gram quantities of 
novel co-crystals and are widely used for preparation.53 Once new materials have been discovered and 
the evaluation of relevant physicochemical properties has informed the selection of the most promising 
forms for a particular application, it is of considerable interest to identify efficient and rapid means of 
scaling-up these novel crystalline forms to allow further testing or exploitation of the new materials at 
larger scales. Although the twin screw extruder method provides a good alternative for making co-
crystals with scale-up potential, speed and solvent free conditions, it does have limitations. For example, 
it can only be applied to systems with pure components, cannot be used for purification purposes, and it 
is not suitable for thermally unstable chemicals such as ALA as elevated temperature is required for the 
formation of pure co-crystals.50, 51 Achieving scale-up of co-crystal production remains a major 
challenge and there have been a small number of studies describing approaches for scale-up from gram 
to kilogram scales (Table 1).  
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Table 1 Reported studies on co-crystallisation scale-up 
Co-crystal system Scale Method Features Ref 
Carbamazepine (CBZ) 
:nicotinamide (NIC) and 
1 L vessel  Solution cooling 
crystallisation 
Through understanding phase 
diagrams 
53 
CBZ:saccharin 30 g  Solution cooling 
crystallisation 
Based on the solubility of CBZ 54 
Caffeine:Glutaric Acid 0.2 mol/kg  
caffeine in 
1 L vessel 
Solution cooling 
crystallisation  
Using ATR-FTIR to monitor 
concentration 
55 
Caffeine:oxalic acid and 
AMG517:sorbic acid  
200 g  Co-rotating twin screw 
extruder (16 mm) 
Pre-mix two solid 
components; temperature 75 
°C and 115 °C for two co-
crystals 
50 
Ibuprofen:NIC 0.2 kg/hr Co-rotating twin screw 
extruder (16 mm) 
Premix two solid components, 
temperature 70-90 °C 
51 
API 1:benzoic acid and API 
:maleic acid 
2.0 g (API)  Solution cooling 
crystallisation 
Anti-solvent addition to 
achieve the supersaturation 
required for co-crystallisation 
56 
SAR1:benzoic acid 10 kg  Solution crystallisation Using co-crystals for 
purification 
33 
Lamivudine intermediate 
co-crystal with (S)-(-)-
BINOL 
30 kg  Solution crystallisation Separation of enantiomers by 
selective formation of the co-
crystal with (S)-(-)-BINOL 
  34 
 
 
Solution cooling crystallisation is one of the most widely used large scale manufacturing processes in 
the chemical and pharmaceutical industries providing effective purification and control of solid form 
and other particle attributes.57 Mass and heat transfer are key process parameters controlling 
concentration and temperature gradients that can impact on local supersaturation and consequently 
crystal form, morphology, purity and particle size distribution57 during cooling and anti-solvent 
crystallisation. These factors become more critical in co-crystallisation processes due to the need to 
control precisely the process path through multiple solid-liquid equilibria.  
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Continuous reaction, work-up and crystallisation are key operations in the drive towards improving 
manufacture in the chemical and pharmaceutical industries.58-61 Continuous processing offers many 
potential advantages over traditional batch processes including consistent product quality, lower cost, 
small foot print, better process control, more efficient use of reagents, solvents, energy and space whilst 
minimising the production of waste materials and reactor downtime for reactor maintenance and 
cleaning. Whilst there remain challenges in the operation of continuous processing equipment within the 
highly regulated pharmaceutical manufacturing environment, there are significant drives to accelerate 
more widespread adoption of these technologies.59, 62 The continuous oscillatory baffled crystalliser 
(COBC) has been reported to offer advantages in controlling crystallisation processes due to plug-flow 
mixing characteristics and rapid heat transfer properties.63 The COBC is a tubular device containing 
periodically spaced orifice baffles with oscillatory motion superimposed on the net flow64-69 (Fig. 2). 
Mixing in a COBC is provided by the generation and cessation of eddies when the flow interacts with 
the baffles and is governed by the oscillatory Reynolds number (Reo) and the Strouhal number (St) 
which are normally used to characterise the oscillation intensity applied to the system.64, 65, 70  The 
oscillatory Reynolds number and the Strouhal number are defined as: 
 ܴ݁ ൌ ߨ݂߯௢ ߩܦߤ  
 
ܵݐ ൌ  ܦ ?ߨ߯௢ 
 
where D = column diameter (m), ߯௢= centre-to-SHDNDPSOLWXGHP¦ IUHTXHQF\+]ߩ = density (kg 
m -3) and µ = fluid viscosity (kg m-1s-1).  
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Fig. 2. A schematic diagram of a continuous oscillatory baffled crystalliser (COBC). 
 
A batch OBC can be used to evaluate specific process conditions and linear scale-up from batch OBC to 
COBC has been described63, 65, 71-73 where applying the same dimensionless numbers between systems 
ensures that hydrodynamic similarity remains consistent provided the geometric similarity is kept 
constant.  Excellent heat transfer properties are achieved due to the high specific area per volume 
compared with a stirred tank reactor which can be particularly beneficial in providing precise control 
over cooling crystallisations.  
In this study, the discovery and characterisation of three novel ALA co-crystals which are more stable 
than ALA is presented along with an assessment of the feasibility of scaling-up the co-crystallisation 
process of ALA with nicotinamide (NIC) from tens of mg to kg scale in a COBC. This is the first report 
of the scale-up for a continuous co-crystallisation process in a COBC. 
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EXPERIMENTAL SECTION 
Materials. Nicotinamde (NIC), isonicotinamide (ISN), trans-cinnamamide, nicotinic acid, benzoic 
acid, benzamide, saccharin, urea and all solvents of analytical grade were purchased from Sigma-
Aldrich and used as received. ALA (racemic) was purchased from Molekula. This contained small 
amounts of polymer and therefore was further purified by recrystallisation from a mixture of ethyl 
acetate-hexane (1:4) before co-crystallisation trials. In general, ALA was dissolved in ethyl acetate 
using ultrasound and the hexane was added with stirring. The total ALA:solvent ratio was 1:10 w/w. 
The mixture was filtered using vacuum to remove the insoluble polymer impurity and then slowly 
cooled to 5 °C. The pure solid was collected by filtration. Water used throughout the study was 
ultrapure provided from a Thermoscientic Barnstead RO water purification unit. 
Methods.  
X-Ray Crystallography. X-ray powder diffraction  (XRPD) data was collected from a sample in a 
rotating 0.7 mm borosilicate glass capillary on a Bruker AXS D8-Advance transmission diffractometer 
equipped with T/T geometry, primary monochromated radiation (Cu KĮ O= 1.54056 Å in the range 4 
± 40° 2T  with a 0.016° 2T  step size and  5 or 8 s step-1 count time at room temperature (RT).  
Single crystal diffraction data (SXD) were collected on a Bruker Apex II diffractometer with a charge 
coupled device (CCD) detector and  graphite monochromated Mo KĮ1 UDGLDWLRQȜ = 0.71073 Å) with 
temperature control from an Oxford Cryosystems Cryostream device operating at -150 °C. Diffraction 
data were processed (cell refinement and data reduction) using Bruker SAINT and APEX2 software74, 
and structure solution and refinement were carried out by direct methods using SHELXS97 and 
SHELXL75 respectively, accessed through the program package WinGX.76  
Infrared Spectroscopy. Infrared (IR) spectra were obtained on a Nicolet S10 Smart ATR FT-IR 
spectrometer using OMNIC program (version 8.1). Solid samples were directly analysed without the 
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need for any prior sample preparation, and the data was collected within a range of 600-4000 cm-1 at 
RT. 
Thermal Analysis. Differential scanning calorimetry (DSC) and thermogravimetric (TG) data were 
collected simultaneously on a NETZSCH STA 449C Instrument under nitrogen atmosphere using 
NETZSCH software. Samples were placed in a 25 PL aluminium crucible and analysed at a heating rate 
of 10 °C min-1. To determine thermal stability samples were heated at 10 °C min-1 to a temperature until 
the samples were completely melted; then the melt was subsequently cooled quickly to -50 °C, and 
heated again at 10 °C min-1 to 300 °C.  
Stability by HPLC. The material was dried for 35 minutes and dissolved in isopropanol before filtering 
through a 0.45 Pm syringe filter. Quantification was carried out by a Varian Prostar HPLC system 
using a standard calibration curve. HPLC column: Waters Spherisorb ODS2, 5 µm, 4.6 x 250 mm. 
Mobile phase: 500: 300: 200 (v/v, pH 2.8 buffer solution: acetonitrile: methanol). A UV detector was 
used at 330 nm. 
Preparation of Co-crystals by Liquid-assisted Grinding. Equimolar amounts of ALA and co-crystal 
former (1:1 molar ratio) to a total weight of ca. 100 mg and a drop of ethanol were mixed and placed in 
the ball mill chamber of a Retsch MM400 mixer mill. The sample was milled at 25 Hz for 5 minutes. 
Preparation of Co-crystals by Solution Crystallisation. Saturated solutions of ALA and selected co-
formers were prepared individually in appropriate solvents at RT and mixed in a 10 mL vial. Half of the 
solution was left at -10 °C and the other half of the solution was left at RT for slow evaporation. Solids 
formed were filtered and analysed by XRPD, DSC and FT-IR. Eight co-formers were used in the trials 
including NIC, ISN, nicotinic acid, benzoic acid, benzamide, trans-cinnamamide, saccharin, urea 
(chemical structures are provided in the ESI).  
Polymorph Screen of ALA:NIC Co-crystals. A single crystal of ALA:NIC co-crystal was grown from 
the saturated solution of ALA:NIC in 1:1 v/v mixture of IPA:hexane by isothermal solvent evaporation 
at RT. An extensive polymorph screen was carried out using a variety of crystallisation methods 
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including solvent evaporation in pure and co-solvent systems at RT, cooling crystallisation, vapour 
diffusion and liquid diffusion. Various solvent systems were screened for crystallisation including 
methanol, ethanol, isopropanol (IPA), 1-butanol, 1-octanol, cyclohexanol, acetone, acetonitrile, hexane, 
1:1 IPA:hexane, dichloromethane, tetrahydrofuran, 1,4-dioxane, ethyl acetate, butyl acetate, diethyl 
ether, diisopropyl ether, t-butyl methyl ether, cyclohexane, cyclopentane, toluene, water, 
dichloromethane, nitromethane, formamide, 1,2-dimethoxyethane, 1:1 IPA:diisopropyl ether, 1:1 
ethanol:diisopropyl ether, diethyl carbonate and  IPA:water. The resulting solids were analysed by 
XRPD.   
Solubility Measurement of ALA:NIC Co-crystals. Solubility of ALA, NIC and 1:1 ALA:NIC in 1:1 
IPA:hexane was measured in an Avantium Crystalline with built-in cameras for visualisation. Co-crystal 
samples with different concentrations were prepared and dissolution and nucleation temperatures were 
determined using turbidity and imaging method. Heating and cooling rates of 0.5 oC min-1 were applied, 
and a magnetic stirring bar (600 rpm) was used during all the trials to provide an initial estimate of 
crystallisation behaviour.  
Further points in ternary phase diagram were measured at 4 °C, 10 °C and 20 °C by measuring the 
solution concentration and solid form of the slurry with excess solids. This slurry was prepared by 
adding an excess of either ALA and co-crystals or excess NIC and co-crystals in 1:1 IPA-hexane and 
stirred at a fixed temperature for at least 24 hours to ensure the final equilibrium was reached. The 
slurry was filtered, and the solid form was determined by XRPD and the solution compositions were 
measured by HPLC. 
Batch OBC Experiments on Co-crystallisation of ALA:NIC. Batch experiments were carried out in a 
500 mL round-bottom jacketed glass OBC of 50 mm inner diameter. Oscillation frequency and 
amplitude were controlled by a linear motor. Temperature within the OBC was monitored by a Teflon® 
coated thermocouple, and adjusted by a Lauda RP845 programmable bath circulator. A mole equivalent 
of NIC (16 g) and filtered ALA (26.8 g) solution in isopropanol (IPA) were added to 500 ml OBC (total 
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working volume 480 mL). The OBC was oscillated at 1 Hz with 25 mm amplitude. At 35 °C, 240 mL of 
hexane was added (1:1 v/v to IPA), and the mixture was cooled from 35 to 2.5 °C in 1 hour. After 
filtration and drying in a vacuum oven at RT, 30.8 g of yellow co-crystals were obtained.  
Continuous Co-crystallisation of ALA:NIC. The COBC was constructed from 24 m of 16 mm inner 
diameter jacketed glass tubes with a working volume of 4.2 L. Baffles were made of moulded glass 
along the length of the COBC including bends. The fluid oscillation was achieved using a PTFE bellow 
coupled with a linear motor and the frequency and amplitude of the oscillation were controlled via a 
control box. Temperature was controlled through the jacket fluid by six bath circulators and monitored 
by stainless steel thermocouples inserted inside the COBC along the length.     
The experimental conditions listed in Table 2 were used. The solution of ALA and NIC in IPA- hexane 
at 40 °C was pumped into COBC by a peristaltic pump at a flow rate of 70 mL min-1. The COBC 
temperature was reduced along the COBC length with the cooling profile displayed in Table 2. The 
product slurry was collected at the outlet of COBC. The continuous run was stopped after 2 - 3 hours 
continuous run time. Dimensionless numbers for tested operating conditions are tabulated in Table 3.  
 
Table 2 Experimental conditions used for the continuous co-crystallisation trials 
 
Entry Oscillation Cooling Rate Flow Rate Run Time 
1 1 Hz 30 mm 
2.5 oC min-1 from 40 oC to 15 
oC,0.3 oC min-1 from 15 oC to 2.5 
oC,  hold at 2.5 oC for 11 min 
70 mL min-1 120 min 
2 1 Hz  30 mm 
2.5 oC min-1 from 40 oC to 15 oC,  
0.45 oC min-1 from 15 oC to 2.5 
oC,  hold at 2.5 oC for 22 min 
70 mL min-1 120 min 
3 1 Hz  30 mm 
3.5 oC min-1 from 40 oC to 6.6 oC, 
0.45 oC min-1 from 6.6 oC to 2.5 
oC, hold at 2.5 oC for 41 min 
70 mL min-1 with pulse 
seeding with 10 % seeds 
in 50 % IPA-hexane 
155 min  
 
 
Table 3 Dimensionless numbers for operating conditions used  
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Oscillatory Reynolds, 
Reo 
Net Flow Reynolds, 
Ren 
Strouhal,             
St 
Velocity Ratio,  
Ȍ 
1000 80 0.09 12 
 
Residence time distribution studies on  the same COBC system77, show that the vessel dispersion 
number (D/uL)78 is less than 0.01, indicating that the system is operating close to plug flow under the 
operating parameters used in this study.79 
 
RESULTS AND DISCUSSION 
Discovery of ALA Co-crystals  
Eight co-formers with either amide (-CONH2), carboxylic acid (-COOH) or pyridine ring were chosen 
for the co-crystallisation trials based on a crystal±engineering approach. These co-formers were selected 
based on the prior knowledge of the potential for H-bonded supramolecular synthons to be formed 
between carboxylic acid (present in ALA) and complementary functionality of potential co-formers20, 21, 
35, 38 (see ESI). Three novel physical forms of ALA with NIC, ISN and trans-cinnamamide (Fig. 3). 
respectively were obtained from both liquid-assisted grinding and small-scale solution crystallisation. 
These three novel solid forms were analysed by XRPD, which confirmed the formation of a new 
polycrystalline phase in each case (Fig. 4). The ¨pKa values (pKa (base) - pKa (acid)) of ALA (4.70)80 
and NIC (3.40)81, 82 and ALA and ISN (3.61)83  are both negative suggesting these forms are co-crystals 
rather than salts.84, 85  
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Fig. 3.  Chemical structures of three co-crystal formers which yielded novel co-crystals with ALA. 
 
 
Fig. 4. Stack plots of XRPD patterns for (a) ALA, NIC and ALA:NIC co-crystals, (b) ALA, ISN and 
ALA:ISN co-crystals and (c) ALA, trans-cinnamide and ALA:trans-cinnamide co-crystals in the range 
of 2-39° 2ș.  
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Further supporting data including DSC and FT-IR spectra of three novel co-crystal forms are provided 
in the ESI. On the basis of accessible yields of co-crystals, ALA:NIC co-crystals were selected for 
further characterisation and scale-up study.  
 
Crystal Structure Determination of ALA:NIC Co-crystals 
The ALA:NIC co-crystal crystallises in  space group P21/c with three molecules of ALA and NIC each 
in the asymmetric unit. Out of three ALA molecules in the asymmetric unit, two of them are highly 
disordered. One of the disordered ALA molecules is disordered over two positions corresponding to the 
R and S configurations. The other disordered ALA molecule exists in the R configuration and is 
disordered over two positions. The crystal structure data obtained from SXD are reported in Table 4.  
 
Table 4 X-ray crystallographic crystal data, data collection and refinement details of ALA:NIC 
collected at -150(2) °C.  
Crystal Data  Data collection  
Chemical 
formula 
C8H14O2S2·C6H6N2O Diffractometer Bruker APEX-II CCD 
Mr 328.44 Absorption correction Multi-scan SADABS 
Crystal system, 
space group 
Monoclinic, P21/c Tmin, Tmax 0.605, 0.745 
Temperature 
(°C ) 
-150 (2) No. of measured, 
independent and 
 observed [I > 2V(I)] 
reflections 
33254, 9068, 6027   
a, b, c (Å) 26.292 (2), 5.2948 
(4), 34.158 (3) 
Rint 0.052 
D, E, J (°) 90, 90.598 (4), 90 Refinement  
V (Å3) 4754.9 (6) R[F2 > 2V(F2)], wR(F2), 
S 
0.073, 0.215, 1.05 
Z 12 No. of reflections 9068 
Radiation type Mo KD No. of parameters 752 
P (mm-1) 0.35 No. of restraints 873 
Crystal size 
(mm) 
0.15 × 0.10 × 0.03 H-atom treatment H atoms treated by a 
mixture of independent and 
constrained refinement 
  '²max, '²min (e Å-3) 1.41, -0.40 
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Each ALA molecule forms two H-bonds with two NIC molecules. The hydroxyl moiety of the 
carboxylic acid group in ALA acts as a donor for the ring nitrogen atom of one NIC molecule with the 
carbonyl oxygen acting as an acceptor for the amino moiety of the amide group in second NIC (Fig. 5). 
ALA molecules form chains along the c-axis, which stack anti-parallel to each other. NIC molecules 
forms dimers connected by amide-amide supramolecular synthons, which further stack along b-axis. 
The columns of NIC dimers stack along c-axis and are present between antiparallel chains of ALA 
along the a-axis.   
 
Fig. 5. The crystal packing in ALA, viewed down the b-axis. C, N, O, S and H atoms are shown in grey, 
violet, red, yellow and black, respectively. Hydrogen bonds are shown as green dotted lines. Other H 
atoms have been omitted for clarity. 
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Stability Studies of ALA:NIC Co-crystals 
Thermal Analysis. ALA showed a melting endotherm with an onset temperature of 60 °C (Fig. 6a). 
Subsequently quench cooling to -50 °C, and heating up to 70 °C showed a very small endotherm with an 
onset temperature of 50 °C (Fig. 6a). No mass loss was observed in the TG curve during and after 
melting. The above results suggest that the ALA undergoes a transformation on heating to 65 °C. It is 
reported in the literature that ALA undergoes polymerisation when heated above its melting point.8, 9  
 
 
 
Fig. 6. DSC traces of (a) ALA with a melt endotherm (I, green colour) and heating of subsequently 
cooled ALA (II, blue colour) and (b) ALA: NIC co-crystals with a melt endotherm (I, green colour) and 
heating of subsequently cooled co-crystals (II, blue colour). 
 
For ALA co-crystals, the DSC results were markedly different. After the ALA:NIC co-crystals melt at 
~80 oC, the DSC sample was cooled to -50 oC and heated again at the same heating rate. Re-
crystallisation occurred at ~8 ºC with a further melting endotherm featuring the same melting point as 
the starting sample (Fig. 6b). No mass loss was observed in the TG curve which further confirmed the 
stability of the co-crystals. Unlike starting material ALA which polymerised after the melting point, all 
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three novel ALA co-crystals showed no evidence of thermal decomposition/degradation in the tested 
temperature range (20 °C to 160 °C) (see ESI). A very recent thermal study on ALA also showed that the 
presence of an additive increases the thermal stability of the ALA.86  The mechanism by which NIC 
improves the thermal stability of ALA is unclear, however the marked effect is not restricted to the 
crystalline state and is evident above the melting point of ALA and the ALA:NIC co-crystal where the 
components are in the liquid state.  
 
 HPLC Analysis. The results showed that ~38 % of ALA degraded after 30 minutes at 60 ºC, with 18 % 
of ALA remaining after 30 minutes at 80 ºC. In contrast, the co-crystals showed enhanced thermal 
stability as no change in ALA content was observed even after 30 minutes at 80 ºC (Table 5).  The 
Other two co-crystals (ALA:ISN and ALA:trans-cinnamamide) also showed enhanced stability than 
ALA (see ESI).   
  
Table 5 Thermal Stability of ALA and Co-crystals determined by HPLC 
Crystals 
Original ALA 
purity (%) 
ALA purity after 30 
minutes at 60 ºC 
ALA purity after 30 
minutes at 80 ºC 
ALA 100 61.83 17.94 
ALA:NIC co-crystals 100 99.73 99.58 
 
 
Design of a Co-crystallisation Process  
Having selected ALA:NIC as a thermally stable system for further investigation, a continuous cooling 
crystallisation method was investigated to scale-up the production of this co-crystal system. The first 
step was to select a suitable solvent system for the co-crystallisation process that will deliver good 
chemical and physical purity as well as yield  
18 
 
A solvent screen was performed using a variety of solvents to obtain initial information on relative 
solubilities, crystal habit and the relative kinetics of each component in the system. No polymorphism of 
the ALA:NIC co-crystal was observed under any of the crystallisation conditions tested in this study.  
To meet with the capabilities of the COBC system available, the target was to find a suitable solvent 
system that could deliver the required yield (1 kg) from a cooling crystallisation with a mean residence 
time of less than 1 hour. It has been recommended from studies of multiple cooling crystallisation 
systems87 that for an industrial cooling crystallisation process solubility in the range of 50-150 g/L at the 
highest temperature and > 5 g/L at the final temperature are desirable. In this work, whilst IPA was a 
identified as a good solvent for obtaining pure ALA:NIC co-crystals it did not display this ideal profile 
to deliver the required yield and so mixed IPA solvent systems were also tested. ALA:NIC co-crystals 
have a solubility of 229.17 g/L in IPA at 37 °C. It was found that a 1:1 (v/v) IPA-hexane system gave 
more suitable solubility profiles (Fig. 7). In this binary solvent system, ALA has much higher solubility 
than the co-crystals and NIC is also more soluble than the co-crystals in the temperature range of -10 to 
40 °C.  
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Fig. 7. Solubility curves of ALA (A), NIC (B) and ALA:NIC co-crystals (C) in 1:1 IPA-
Hexane in the range -8 to 48°C. 
 
In-situ image analysis during the solubility studies indicated the formation of spherical agglomerates. 
XRPD analysis confirmed the identity and physical purity of the ALA:NIC co-crystals (Fig. 8). 
 
Fig. 8. Spherical agglomerates captured during in-situ image analysis of co-crystallisation in 1:1 IPA-
hexane in an 8 mL stirred tank reactor. 
 
The ternary phase diagram is of value in developing a controlled approach to co-crystal crystallisation.88 
The ternary phase diagram of ALA and NIC in the mixed solvent of IPA-hexane is shown in Fig. 9. The 
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eutectic points were determined based on *LEE¶V SKDVH UXOH89-91 and the critical region in which 
crystallisation of pure co-crystals occurs is shown as the region inside points A, B and C (Fig. 9).  
 
 
 
Fig. 9. (a) Ternary phase diagram of ALA, NIC in 1:1 IPA:hexane at 2 °C, (b) inset highlighting upper 
part of the phase diagram.  
The temperature dependence of the phase diagram was also investigated to inform the process design 
and identify changes in the temperature dependence of the critical region (Fig. 10). The critical region 
becomes narrower as temperature is reduced, largely due to the significant change in ALA solubility, 
emphasising the importance of accurate temperature control throughout the cooling process.  The 
starting concentrations for ALA and NIC and cooling profiles were selected to ensure the crystallisation 
process would be operated within the critical region optimising the purity and yield of the process.  
 
(a) (b)
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Fig. 10. Ternary phase diagram of ALA and NIC in 1:1 IPA-hexane at 2 °C, 9 °C and 20 °C. A, C and 
A1, C1 and A2, C2 are eutectic points at 2 °C, 9 °C and 20 °C respectively. The blue lines delineate the 
critical region at 2 °C, and dotted green and red lines bound the critical regions at 9 °C and 20 °C. ci, cf  
represent starting concentration and final concentration respectively. 
 
In the next step, the co-crystallisation process of ALA and NIC in 1:1 IPA-hexane was scaled-up in a 
500 mL batch OBC to identify the key parameters required for design of the continuous process. These 
include residence time, temperature profile, oscillation frequency and amplitude. The target was to 
enable complete desupersaturation of the solution within the target residence time with an acceptable 
yield and co-crystal purity whilst ensuring complete suspension of particles. The operation temperature 
range was chosen from 40 °C to 2.5 °C using equimolar starting concentrations for ALA and NIC of 
0.27 M (starting concentration ci, and final concentration cf shown in Fig. 10). Oscillatory mixing 
conditions of 1 Hz and 25 mm were selected based on achieving a uniform solid suspension at the 
maximum solid loading. Over 30 g of pure co-crystal was obtained from two repeats (65-71 % yield). 
These experiments also resulted in spherical agglomerates of the co-crystal. Nucleation temperatures 
were higher in the batch OBC than that observed in magnetically stirred vial systems (10 °C in OBC as 
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compared to -2 °C in a vial). This may be due to the high shear rates and/or the scraping effect of the 
moving baffles used in this batch OBC compared to the magnetically stirred vials used in the small-
scale experiments.92  
Pawley type refinement of the of the lattice parameters of the ALA-NIC co-crystal obtained from SXD 
against the XRPD data of the samples obtained from OBC experiments showed a good fit (Rwp = 4.12)  
(see ESI), confirming the crystal structure obtained from SXD is representative of the bulk sample. 
FTIR and thermal analyses were also employed to confirm the purity of the co-crystals obtained from 
OBC experiments.  
 
Continuous Crystallisation of ALA:NIC Co-crystals in a COBC.  
The scale-up design and operation in the COBC was carried out by implementing similar oscillatory 
conditions as identified from the batch OBC experiments described above. To achieve reliable 
nucleation of the co-crystal in the cooling process, seeding was used by pumping 10 % w/w co-crystal 
seed suspension for 10 s at 10 °C. No further seeds were required after initiation of nucleation in the 
COBC. Further work is ongoing to understand the nucleation mechanisms given the operating 
conditions used in the COBC.  
Three COBC trials were completed, running for up to 3 residence times. Solid content and particle size 
distributions were monitored from the outlet stream using focused beam reflectance measurement 
(FBRM). The product slurry had a solid content of 78 g/L equivalent to a production throughput of 330 
g/hr of solid co-crystals. Fig. 11 shows the crystallisation of the ALA:NIC product at different positions 
in the COBC during operation.  
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Fig. 11 Co-crystallisation in a COBC (a) at residence time (RT) = 12 minutes and shows the 
early stages of growth; (b) RT = 20 minutes and (c) RT = 40 minutes show the progression of 
crystal growth. 
 
No signs of fouling or potential blockage were observed during these trials. SEM images of the co-
crystals produced in the COBC showed that the co-crystals were spherical agglomerates comprising 
multiple small thin plates (Fig. 12). The co-crystals obtained from the COBC had a relatively narrow 
PSD as shown by SEM and FBRM (Fig. 12 and Fig. 13). 
 
 
 
 
 Fig. 12 SEM images of dried ALA:NIC co-crystals from the continuous trial. 
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 Fig. 13 Chord length distribution measured using FBRM for ALA:NIC co-crystals produced from the 
continuous co-crystallisation process in a COBC. 
 
 
CONCLUSION 
Three novel ALA co-crystals were discovered and characterised by XPRD, FTIR and thermal analysis. 
The crystal structure ofthe ALA:NIC co-crystal was determined using  SXD revealing the molecular 
packing in this novel solid form. In addition to highlighting the specific intermolecular interactions 
within the lattice, the single crystal structure also provides an unambiguous means for physical 
identification of the co-crystal product produced using different crystallisation approaches.  Here, a co-
crystal product was shown to have enhanced thermal stability compared with pure ALA conferring 
significant advantages for production and storage of this material. Given the increased interest in the 
prediction, discovery and characterisation of novel functional co-crystalline materials across different 
application areas approaches for rapid scale-up are also of considerable interest. This study has 
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demonstrated the rapid translation of a novel co-crystal material from gram to kilogram scale in the 
laboratory using continuous crystallisation in a COBC supported by a systematic approach to process 
design. Agglomerated spherical co-crystals were produced continuously at a throughput of 330 g/hr of 
solid at a laboratory scale in good purity and narrow particle size distributions. Further work is required 
to detail the mechanism of nucleation following seeding and agglomeration in this process. The use of 
on-line PAT techniques such as IR, UV or Raman as well as imaging (e.g. PVM) are very useful tools 
for more advanced process understanding and control.93, 94 The increased range of technologies 
becoming available for continuous crystallisation at laboratory scale provide an important approach 
route to accelerate the exploitation of novel materials through their consistent production at larger scales 
using continuous processing. 
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